Alexion Pharmaceuticals (ALXN) Shares are Down -3.68%

Alexion Pharmaceuticals (ALXN) : During the past 4 weeks, traders have been relatively bearish on Alexion Pharmaceuticals (ALXN), hence the stock is down -0.38% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -3.84% relative to the S&P 500. The 4-week change in the price of the stock is -0.91% and the stock has fallen -3.68% in the past 1 week.

The stock has recorded a 20-day Moving Average of 3.9% and the 50-Day Moving Average is 5.87%.The 200 Day SMA reached 13.73%


Alexion Pharmaceuticals (NASDAQ:ALXN): After opening at $120.11, the stock dipped to an intraday low of $119.23 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $123.05 and the buying power remained strong till the end. The stock closed at $122.54 for the day, a gain of 2.07% for the day session. The total traded volume was 1,892,733. The stocks close on the previous trading day was $122.54.

Alexion Pharmaceuticals (ALXN) : Average target price received by Alexion Pharmaceuticals (ALXN) is $171.47 with an expected standard deviation of $35.97. The most aggressive target on the stock is $221, whereas the most downbeat target is $92. 15 financial analysts are currently covering the stock.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *